Literature DB >> 15955204

Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.

Jing Yuan Fang1.   

Abstract

Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl moiety from acetyl coenzyme A to the lysine, and histone deacetylases (HDAC) remove the acetyl groups re-establishing the positive charge in the histones. HDAC inhibitors have antiproliferative activity against human cancer cells via cell cycle arrest, pro-differentiation, and pro-apoptosis. In recent years, many studies have shown that specific HDAC inhibitors are helpful for gastrointestinal cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955204     DOI: 10.1111/j.1440-1746.2005.03807.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

Review 2.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.

Authors:  Marion Ganslmayer; Annette Zimmermann; Steffen Zopf; Christoph Herold
Journal:  World J Gastroenterol       Date:  2011-08-21       Impact factor: 5.742

Review 5.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 6.  Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis.

Authors:  Shimaa Hassan AbdelAziz Soliman; Arturo Orlacchio; Fabio Verginelli
Journal:  Microorganisms       Date:  2021-05-30

7.  Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.

Authors:  Tae Won Kwak; Do Hyung Kim; Young-Il Jeong; Dae Hwan Kang
Journal:  J Nanobiotechnology       Date:  2015-09-26       Impact factor: 10.435

8.  Histone hypo-acetylation of Sox9 mediates nicotine-induced weak cartilage repair by suppressing BMSC chondrogenic differentiation.

Authors:  Kai Tie; Min Wu; Yu Deng; Yinxian Wen; Liaobin Chen; Hui Wang
Journal:  Stem Cell Res Ther       Date:  2018-04-10       Impact factor: 6.832

9.  Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma.

Authors:  Masumeh Sanaei; Fraidoon Kavoosi
Journal:  Res Pharm Sci       Date:  2021-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.